Alumis (ALMS) Total Non-Current Liabilities (2025)
Alumis' (ALMS) quarterly Total Non-Current Liabilities came in at $110.4 million in Q4 2025, up 7.14% on a QoQ basis from $103.1 million in Q3 2025.
Alumis (ALMS) Total Non-Current Liabilities (2025) Analysis & Trends
Alumis (ALMS) has 1 years of Total Non-Current Liabilities data on file, last reported at $110.4 million in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $110.4 million in Q4 2025; TTM through Dec 2025 was $110.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $110.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $110.4 million, up from $103.1 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ALMS reached as high as $125.4 million in Q2 2025 and fell as low as $103.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Alumis | 2.41 Bn | 2.10 Bn | - | 110.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110.44 Mn |
| Sep 30, 2025 | 103.07 Mn |
| Jun 30, 2025 | 125.43 Mn |